argenx SE said it will acquire Forte Biosciences, adding FB102, an experimental autoimmune drug, to its portfolio. The move broadens argenx's early-stage pipeline, potentially elevating long-term growth if FB102 advances, but no deal terms or trial timelines were disclosed. The announcement signals ongoing consolidation in the autoimmune space and could act as a new catalyst if data flow improves.
argenx said Vyvgart global sales increased in Q2 2026 versus a year earlier, signaling improving demand for the lead therapy. The report provides no specific sales figures or margin details, but the implied top-line momentum could support near-term sentiment and potentially lift ARGNF's valuation if the trend persists into future quarters.
